$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Early diagnosis and detection improves survival outcomes in EGFR+ non-small cell lung cancer - Kanghule
2025-10-19 11:44:20
Check Details
New targeted drug D-0316 has clinically significant efficacy in treating T790M+ and EGFR+ non-small cell lung cancer
2025-10-19 11:44:20
Check Details
New dosing regimen of pozitinib has better efficacy and tolerability in the treatment of non-small cell lung cancer_ Kanghule
2025-10-19 11:44:20
Check Details
New hope for c-Met+ non-small cell lung cancer, Telisotuzumab Vedotin is coming!
2025-10-19 11:44:20
Check Details
What patients with lung cancer need to know about using afatinib_Cortex
2025-10-19 11:44:20
Check Details
Afatinib has significant effect in the treatment of advanced lung squamous cell carcinoma_ Kanghule
2025-10-19 11:44:20
Check Details
The occurrence and treatment options of lung squamous cell carcinoma
2025-10-19 11:44:20
Check Details
The therapeutic effect of taking the targeted drug crizotinib in late-stage lung cancer
2025-10-19 11:44:20
Check Details
How effective is afatinib in the treatment of advanced lung squamous cell carcinoma?
2025-10-19 11:44:20
Check Details
What to do after afatinib is resistant to lung squamous cell carcinoma?
2025-10-19 11:44:20
Check Details
Contraindications and medication precautions for patients taking crizotinib
2025-10-19 11:44:20
Check Details
Crizotinib has significant efficacy in treating ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
1
2
...
3863
3864
3865
3866
3867
3868
3869
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
2
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
3
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
4
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
5
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
6
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
7
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
8
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
9
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
10
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
11
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
12
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum